Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib (SHR0302) in moderate to severe atopic dermatitis
NCT04162899Phase 2Completed
- Sponsor
- Reistone Biopharma
- Start
- Nov 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ivarmacitinib in atopic dermatitis (AD) (3 arms), sponsored by Reistone Biopharma. Primary endpoint: Investigator's Global Assessment Response at 12 weeks. Started Nov 2019; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04162899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04162899.